

Ministry of Health

COVID-19 Vaccine Series Second Dose Eligibility Quick Reference

Version 3.0 July 6, 2021

This guidance provides basic information only. This document is not intended to provide or take the place of medical advice, diagnosis or treatment, or legal advice.

- Please check the Ministry of Health (MOH) [COVID-19](#) website regularly for updates to this document, mental health resources, and other information,

This guidance is applicable for all 2-dose COVID-19 vaccines series in Ontario and based on current vaccine availability.

What is new in the Version 3.0?

- All Ontarians aged 12+ are eligible to book second dose vaccine appointments starting July 5th

All Ontarians aged 12 and over

- **Starting July 5th** all Ontarians aged 12 and over who have received their first dose of a COVID-19 vaccine will be eligible to book their second dose appointment with the following dose intervals:

Dose Intervals		
Pfizer-BioNTech	Moderna	AstraZeneca/COVISHIELD
<ul style="list-style-type: none"> • Product monograph authorized interval of 21 days; an interval of 28 days may be considered for operational feasibility.¹ 	<ul style="list-style-type: none"> • Product monograph authorized interval of 4 weeks (28 days).¹ 	<ul style="list-style-type: none"> • Individuals may choose to have a second dose of an AstraZeneca COVID-19 vaccine or an mRNA vaccine at an interval of no less than 8 weeks.²

¹ Where a different product is used to complete the vaccine series, the second dose should be given at the Health Canada product monograph authorized interval of the vaccine used for the first dose, or as soon as operationally feasible thereafter. See the [Q&A for Health Care Providers on Mixed COVID-19 mRNA Vaccine Schedules](#).

² See [COVID-19 Vaccine Information for Individuals that received a first dose of the AstraZeneca COVID-19 vaccine/COVISHIELD vaccine](#) for support on decision making and more information.

Mixed mRNA Vaccine Series Intervals

Vaccine for first dose	Vaccine for second dose	Earliest Interval between doses†
Pfizer	Pfizer	21 days*
Pfizer	Moderna	21 days*
Moderna	Moderna	28 days
Moderna	Pfizer	28 days

† per the product monographs of the vaccine used for the first dose

*Note: an interval of 28 days may be considered for operational feasibility

Individuals who are recipients of, undergoing or imminently starting³:

- Transplants (including solid organ transplant and hematopoietic stem cell transplants)
- Hemodialysis or peritoneal dialysis
- An **anti-CD20 agent** (e.g., rituximab, ocrelizumab, ofatumumab)
- Stable, active treatment[‡] (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders
- Stable, active treatment[‡] (chemotherapy, targeted therapies, immunotherapy) for non-hematologic malignant solid tumors

[‡]**Note:** This excludes individuals receiving solely hormonal therapy and/or radiation therapy

Dose Intervals ^{**}		
Pfizer-BioNTech	Moderna	AstraZeneca/COVISHIELD
<ul style="list-style-type: none"> • Product monograph authorized interval of 21 days^{**}; an interval of 28 days may be considered for operational feasibility.⁴ 	<ul style="list-style-type: none"> • Product monograph authorized interval of 4 weeks (28 days).^{** 4} 	<ul style="list-style-type: none"> • Individuals may choose to have a second dose of an AstraZeneca COVID-19 vaccine or an mRNA vaccine at the product monograph interval of 4-12 weeks.^{**5}

^{**}The timing of the vaccine may be decided with the treating provider in collaboration with clinic sites in order to optimize the immune response from the vaccine series and minimize delays in management of the individual's underlying condition.

³ See the [Vaccine Clinical Advisory Group \(VCAG\) Recommendations on Exceptions to Extended Dose Intervals for COVID-19 vaccines](#) for more information.

⁴ Where a different product is used to complete the vaccine series, the second dose should be given at the Health Canada product monograph authorized interval of the vaccine used for the first dose, or as soon as operationally feasible thereafter.

⁵ See [COVID-19 Vaccine Information for Individuals that received a first dose of the AstraZeneca COVID-19 vaccine/COVISHIELD vaccine](#) for support on decision making and more information.